Video

Module 3: Urothelial Carcinoma

Activity Overview

This educational activity is an archive of the live conference held on March 13-14, 2026.

Target Audience

This educational activity is directed toward medical, surgical, and radiation oncologists involved in the treatment of patients with GU malignancies. Urologists, fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, nuclear medicine physicians, and other health care professionals interested in the treatment of GU malignancies may also participate.

Learning Objectives

  • Interpret advanced diagnostic and molecular testing strategies—including ctDNA and genomic profiling—for risk stratification and disease monitoring in GU malignancies
  • Integrate emerging therapies with multidisciplinary strategies to optimize treatment sequencing and coordination across specialties
  • Apply molecular and genomic test results to guide treatment selection and personalize care in patients with GU cancers
  • Integrate emerging therapies with multidisciplinary strategies to optimize treatment sequencing and coordination across specialties
        Module 3: Urothelial Carcinoma

        GET STARTED WITH THIS PROGRAM:

        Register now to gain access to this program.

        Create AccountAlready Registered? Login Here

        Accreditation/Credit Designation

        Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

        Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

        Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 3.25 Contact Hours.

        Acknowledgment of Commercial Support

        This activity is supported by educational grants from Exact Sciences Corporation and Exelixis, Inc.

        Follow Us on Social Media!

        Course

        Module 3: Urothelial Carcinoma

        Create Account